WO2001012230A1 - The nasal transmucosal delivery of peptides conjugated with biocompatible polymers - Google Patents
The nasal transmucosal delivery of peptides conjugated with biocompatible polymers Download PDFInfo
- Publication number
- WO2001012230A1 WO2001012230A1 PCT/KR2000/000868 KR0000868W WO0112230A1 WO 2001012230 A1 WO2001012230 A1 WO 2001012230A1 KR 0000868 W KR0000868 W KR 0000868W WO 0112230 A1 WO0112230 A1 WO 0112230A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peg
- pharmaceutical composition
- transmucosal delivery
- peptide
- nasal
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 62
- 238000012384 transportation and delivery Methods 0.000 title claims abstract description 37
- 229920000249 biocompatible polymer Polymers 0.000 title claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 title description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 229920001223 polyethylene glycol Polymers 0.000 claims description 70
- 229920000642 polymer Polymers 0.000 claims description 25
- 239000000199 parathyroid hormone Substances 0.000 claims description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 13
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 13
- 229960001319 parathyroid hormone Drugs 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- -1 polyoxyethylene Polymers 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 102100033367 Appetite-regulating hormone Human genes 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 210000003016 hypothalamus Anatomy 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 239000003488 releasing hormone Substances 0.000 claims description 3
- 229920003169 water-soluble polymer Polymers 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 102000011923 Thyrotropin Human genes 0.000 claims description 2
- 108010061174 Thyrotropin Proteins 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 230000002992 thymic effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 34
- 229940079593 drug Drugs 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
- 210000003928 nasal cavity Anatomy 0.000 abstract description 8
- 108091005804 Peptidases Proteins 0.000 abstract description 5
- 239000004365 Protease Substances 0.000 abstract description 5
- 230000007423 decrease Effects 0.000 abstract description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 4
- 239000000863 peptide conjugate Substances 0.000 abstract description 4
- 206010013654 Drug abuse Diseases 0.000 abstract description 2
- 208000011117 substance-related disease Diseases 0.000 abstract description 2
- 239000000562 conjugate Substances 0.000 description 41
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 26
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 23
- 229910052791 calcium Inorganic materials 0.000 description 23
- 239000011575 calcium Substances 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 21
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 17
- 230000009467 reduction Effects 0.000 description 17
- 102000055006 Calcitonin Human genes 0.000 description 16
- 108060001064 Calcitonin Proteins 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 16
- 229960004015 calcitonin Drugs 0.000 description 16
- 238000002955 isolation Methods 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 7
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 7
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 6
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 6
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 229940124532 absorption promoter Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 239000003777 experimental drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- LRMSQVBRUNSOJL-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)F LRMSQVBRUNSOJL-UHFFFAOYSA-N 0.000 description 3
- QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108010068072 salmon calcitonin Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100038518 Calcitonin Human genes 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 238000003650 Calcium Assay Kit Methods 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical group NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000002434 gonadorelin derivative Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002807 parathyroid gland hormone Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960000208 pralmorelin Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a pharmaceutical composition for a nasal transmucosal delivery, comprising a biologically active peptide, which is sparingly soluble in water, con ugated with an active biocompatible polymer.
- the present invention relates to the pharmaceutical composition containing the biocompatible polymer-biologically active peptide conjugate suitable for use in the nasal transmucosal delivery, which is highly improved m water solubility and protected from being degraded by protease.
- the pharmaceutical composition comprising of the peptide-polymer conjugate for the nasal transmucosal delivery of the present invention allows drug activity to be expressed in a short period of time and improves a bioavailability .
- peptides or proteins are very low in body absorption efficiency because they are easily hydrolyzed or degraded by enzymes within a short period of time after being taken into the body. Further, when such peptide medicines are repetitively administered, immune reactions are frequently induced to produce antibodies which may cause so serious hypersensitivity as to menace the life of the administee, acting as a neutralizing role against the physiological activity of the medicines. In addition, the clearance attributable to the reticuloendothelial system (RES) is increased. Therefore, most of peptide medicines have been administered by injection, thus far. Injection administration, however, gives patients pain, accompanying dangers. Particularly, patients who need to be treated for a long period of time may not be able to treat themselves by injection. Thus, there remains a need to develop other routes for peptide administration .
- RES reticuloendothelial system
- An adult's nasal cavity is coated with a mucosa at a thickness of 2.0-4.0 mm (Mugind, Nasal Allergy, Blackwell Scientific, Oxford, 1979) and has a volume
- the nasal cavity allows drug activity to be expressed in a short period of time because of its being abundant in fine villus and large in absorption surface area. Accordingly, extensive research has been made on the transmucosal delivery of drugs.
- Factors which have influence on the absorption of drugs through mucosae include physical and chemical properties of drugs, such as drug' s inherent transmittance, ion strength, flow distribution coefficient and molecular weight, carrier transportation, protease degradation, and physiological conditions of nasal mucosae.
- the nasal mucosa is a direct absorption route through which drugs can circumvent the liver metabolism, which is a great hindrance to the utilization of drugs in the body upon oral administration.
- the nasal transmucosal route has an advantage over the oral route in that the body utilization of drugs can be significantly improved.
- the nasal transmucosal delivery of peptides or proteins of large molecular weights are lower m absorption efficiency than intravenous injection because the peptides or proteins cannot well pass through nasal mucosae.
- Absorption promoters have been suggested to improve the absorption of peptides. Examples of suggested absorption promoters include surfactants (Hirai et al . , In t . J. Pharm .
- European Pat. Nos. 23,359 and 122,023 open the possibility that a powder formulation of peptide drugs is delivered through nasal mucosae.
- U. S. Pat. No. 4,250,163 discloses a mucosa-adsorptive substance which is admixed with a powder form of peptides drugs to enhance the nasal transmucosal delivery of the drugs.
- European Pat. No. 123,831 is directed to the administration of steroids through nasal mucosae. Germany Pat. No. 2,620,446 describes a body absorption enhancer which is effective for the nasal transmucosal delivery of insulin.
- PCT/GB/86/00721 discloses a formulation technique of drugs into microspheres which can be delivered through nasal mucosae. However, this formulation technique can be applied only to particular drugs.
- Japanese Pat. No. Sho . 58-189118 cyclodextnn is utilized for the nasal transmucosal delivery of peptides.
- Japanese Pat. No. Sho. 59-89619 discloses ethereal surfactants, for example, polyoxyethylene lauryl ether, as neutral absorption enhancers for nasal transmucosal delivery.
- these surfactants are not suitable for clinical use because they cause damage to nasal mucosae.
- Japanese Pat. No. Sho. 61-118325 describes alkaline or neutral amino acids for use m the nasal transmucosal delivery of calcitomn.
- sucrose fatty acid ester is used as an absorption promoter for the nasal transmucosal delivery of drugs.
- these absorption promoters are also toxic to mucosae.
- the above-mentioned reference patents most of which are based on the sustained release of peptide drugs, enable drugs to be released continuously, but cannot solve the problem m that peptides or protein drugs administered through mucosae are degraded m a short period of time. These conventional techniques find difficulty m being applied for the nasal transmucosal delivery of peptide drugs.
- Conjunction of pharmaceutically active proteins or molecules to synthetic macromolecules may afford great advantages when they are applied m vivo and in vi tro .
- physiologically active molecules When being covalently bonded to macromolecules, physiologically active molecules may be changed in surface properties and solubility. For example, an increase may be brought into their solubility m water or organic solvents.
- macromolecules may make the conjugated peptides more stable m vivo as well as reduce the clearance attributed to the intestinal system, the kidney, the spleen and/or the liver.
- conjunction of polymers to peptides can bring about a great improvement m the stability of the peptides in solutions and effectively protect the intrinsic surface properties of peptides to prevent non-specific protein adsorption.
- U. S. Pat. No. 4,179,337 discloses conjugates between peptides or polypeptides and polyethylene glycol (hereinafter, referred to as "PEG") with a molecular weight of 500-20,000 or water-soluble polymers, which are reduced in antigenicity and anti- lmmunity while maintaining the biological activity of the peptides or polypeptides. It is described in U. S, Pat. No. 4,301,144 that hemoglobin is increased in oxygen molecule-carrying potential when being associated with PEG or water-soluble polymers.
- PEG polyethylene glycol
- the conjugation of PEG to polypeptides is achieved by reacting activated PEG to amino residues of polypeptides. Suitable for use in this purpose are a lysme residue and N-termini .
- PEG activation one of the hydroxy groups of PEG is substituted with a methyl ether group while the other hydroxy group is bonded to an electrophile functional group (Abuchowski, A. and Davis, F. F. (1981), in Enzymes as Drugs (Holsenberg, J. and Roberts, J. , eds . ) ) .
- activated polymers include PEG-N-hydroxysuccmeimide-activated esters, which contain amide bonds, PEG-epoxides and PEG- tresylate, which contain alkyl bonds, PEG-carbonyl lmidazole and PEG-nitrophenyl carbonates, which contain urethane bonds, PEG-aldehyde, which contains a Schiff' s base at the N-terminus .
- PEG derivatives able to specifically react to cystein groups of polypeptides include PEG- vi ⁇ yl sulphone, PEG-iodoacetamide, PEG-maleimide, and PEG-orthopyridyl disulfide with most preference to male mide-containing PEG.
- PEG-vmyl sulfone is best m view of the stability in water solutions while PEG- orthopyridyl disulfide can be reversibly degraded in vivo because of the presence of disulfide bonds.
- Peptides taking advantage of these derivatives can be exemplified by mterleu ⁇ n-3 and ⁇ nterleuk ⁇ n-2.
- PEG derivatives reactive specifically to oligo sugars of polypeptides may be exemplified by PEG- hydrizide, which is able to react with aldehyde- containing compounds to form relatively stable hydrozone bonds. Advantage is taken of the specific bonding of PEG-hydrizides to sugar moieties of glycoproteins .
- PEG-isocyanates react specifically with hydroxy groups of polypeptides.
- PEG derivatives containing phenylglyoxal which is highly reactive to the guanidmo group.
- the nasal transmucosal delivery of peptides alone is significantly improved absorption efficiency compared with the oral administration because the peptides are not subjected to liver metabolism, but poor in the bioavailability of the peptides because they are degraded by endogenous enzymes.
- a pharmaceutical composition for the nasal transmucosal delivery comprising a sparingly soluble, biologically active polypeptide conjugated with an activated biocompatible polymer.
- the present invention have confirmed that, when the polymer- peptide conjugate is administered through the nasal cavity, it is improved in water solubility and protected from being degraded by proteases, whereby the medicinal activity of the pharmaceutical composition can be sustained for an extended period of
- the present invention provides a pharmaceutical composition for the nasal transmucosal delivery, comprising a sparingly soluble, biologically active polypeptide conjugated with an activated biocompatible polymer.
- FIG. 1 represents a result of size exclusion chromatography which isolates sCT and PEG-sCT, where
- FIG. 2 shows a pH effect to the production of mono-PEG-sCT that PEG is conjugated with N-termmus of calcitonin, Lys 18 or Lys 11 , where I ; mono-PEG-sCT (N-terminal conjugate) ,
- FIG. 3 shows a molar ratio effect of calcitonm : sCT to the production of mono-PEG-sCT that PEG is conjugated with N-termmus of calcitonm, Lys 18 or Lys 11 , where ⁇ ; mono-PEG-sCT (N-termmal conjugate),
- FIG. 4 shows a reaction time effect of calcitonm : sCT to the production of mono-PEG-sCT that PEG is conjugated with N-termmus of calcitonm, Lys 18 or Lys 11 , where
- FIG. 5 represents a result of size exclusion chromatography which isolates hPTH and PEG-hPTH ( 1-34 ) , where
- FIG. 6 shows a reduction effect of calcitonm concentration m blood when sCT and PEG-sCT conjugate are administered through the nasal cavity, where A ; sCT,
- FIG. 7 shows a calcium reduction effect of isolated mono-PEG-sCT isomers
- mono-PEG-sCT (Lys n -conjugate, M3), ⁇ ; sCT, D ; mono-PEG-sCT not isolated its isomers.
- biocompatible polymers as used herein means naturally occurring or synthetic compounds which are dissolved in water.
- the biocompatible polymers include polyethylene glycol, polypropylene glycol (PPG), polyoxyethylene (POE), polytrimethylene glycol, polylactic acid and its derivatives, polyacrylic acid and their derivatives, polyamino acid, polyvinyl alcohols, polyurethane, polyphosphazene, poly(L- lysine) , polyalkylene oxide (PAO), and water-soluble polymers such as polysaccharide, dextran, and non- immumogenic polymers such as polyvinyl alcohol and polyacryl amide.
- the present invention provides a peptide-polymer conjugate for a nasal transmucosal delivery, which can be prepared by bonding an activated polymer to a biologically active peptide.
- the bond between the peptides and the polymers may be a covalent bond or a non-covalent bond such as a lipophilic bond or a hydrophobic bond.
- the molar ratio of polypeptides to activated polymers are in the range of about 1:1 to 1:10 and preferably in the range of 1:1 to 1:7.
- one to three activated polymers may be conjugated to one polypeptide molecule.
- Peptide-mono polymer conjugates exert the most effective pharmaceutical activity.
- PEG can be conjugated to the N- termmus of calcitonm and/or Lys 18 and/or Lys 11 .
- the calcitonm- (mono) PEG conjugate in which one PEG molecule is conjugated to one calcitonm molecule exhibits the highest calcium reduction effect.
- a conjugate isomer m which PEG is conjugated to the N- termmus or the Lys 18 shows more sustained and effective calcium reduction activity than does a conjugate isomer in which PEG is conjugated to Lys 11 .
- pH 5, 6 or 7 of the reaction solution more than 80 % of PEG is conjugated to the N-termmus of calcitonm.
- pH 8 or higher PEG is increasingly conjugated to Lys 11 and Lys 18 . In contrast, changes in reaction time and molar ratio cannot affect the proportion of isomers.
- the binding reaction of the peptide-activated polymer in the present invention is performed m 0.1 M phosphate buffer ranged, m pH, from 6 to 9, at 0 to 25C° of reaction temperature for several minutes to 12 hours.
- a method of polymer activation consists of the following steps of; preparing the polymer into polyalkylene oxide (hereinafter, referred to as "PAO") such as monoethoxy-poly (ethylene glycol, mPEG) ; and changing the other part of PAO into a reaction group having reactivity.
- PAO polyalkylene oxide
- the activated polymer forms the prptide-polymer conjugate by reacting with ⁇ -amme group of lysme.
- the peptide can be used as a conjugated moiety.
- the present inventors have measured the blood concentration of peptide according to time after the peptide-polymer conjugate is administered to rats through the nasal cavity. Thus, the present inventors have confirmed that the peptide by the nasal transmucosal delivery has a better stability living body and sustains its biological activity for a long time .
- the peptide of the present invention is not limited to the specific therapeutic agents but applied to the all substances having biological activity, particularly, it is desirable to use calcitonin, parathyroid hormone (hereinafter, referred to as "PTH”).
- PTH parathyroid hormone
- insuline synthetic enkephalin
- GHRP growth hormone releasing peptide
- LHRH leutenizing hormone releasing hormone
- CGRP calcitonin gene related peptide
- THF thyroid stimulating hormone and thymic humoral factor
- Calcitonin is a single chain peptide composed of 32 amino acids, forms a ring at N-terminus and has a proline amide group at C-terminus. Calcitonin inhibits a bone absorption by acting directly to osteoclast and is used for cure of hypercalciumia, Pajet's disease, pain from the bone absorption and osteporosis. Calcitonin is produced in salmon, eel, human, pig, etc., and salmon and eel calcitonin have the most effect.
- Parathyroid hormone (PTH) is a peptide hormone composed of 84 ammo acids and secreted from parathyroid.
- parathyroid cell Since parathyroid cell has a recognition site for calcium concentration, PTH secretion increases when calcitonm is lower, and PTH secretion decreases when calciton higher. PTH increases a calcium absorption taken from foods at the small intestine, transfers calcium from bone to blood, and , finally, increases a blood calcium concentration.
- the major active site of PTH is adrenal cortex. PTH binds to the membrane of adrenal cortex to increase the production of cAMP, IP 3 (mos ⁇ tol triphosphate) and DAG(d ⁇ acyl glycerol) .
- Insulin is a peptide composed of A chain and B chain.
- a chain composed of 21 ammo acids and B chain composed of 30 ammo acids are connected by 1 pair of disulfide bond. Disulfide bond exists between 6 th ammo acid of A chain and 11 th ammo acid of B chain.
- Disulfide bond exists between 6 th ammo acid of A chain and 11 th ammo acid of B chain.
- Enkephalm is a pentapeptide representing a similar action to opium. Enkephalm is devided into two groups of methionme enkephalm and leucme enkephalm according to C-termmus bounded to Try-Gly- Gly-Phe. Enkephalm inhibits pain from transferring to bram by preventing a release of substance P from the end of analgesic nerve fiber.
- Growth hormone releasing peptide presents m the form of hepta and hexa and affects a release of growth hormone.
- the growth hormone releasing effect of GHRP is related to a dose, increases until aldolescence and decreases after then.
- GHRP-6 is a hexapeptide having a structure of H ⁇ s-Asp-Try-Ala-Try-Asp-Lys-NH 2 , and is very stable in acetate buffer ranged, in pH, from 5.5 to 6.0. In case of oral administration, bioavailability of GHRP-6 is 0.3%, an absorption half life is 15 minutes, and an elimination half life is 60 minutes. GHRP-6 secrets selectively growth hormone through a receptor in hypothalamus and pituitary gland.
- LH-RH is a hypothalamus peptide and stimulates the relases of LH and follicle stimulating hormone.
- LH-RH regulates a function of brain and many peripheral organs by binding to receptors on the targeted cell surface.
- LH-RH has a decapeptide structure of Pyro-Glu-His-Trp-Ser-Tyr-Gly- Leu-Arg-Pro-Gly-NH 2 , and is degraded in tubular of the kidney.
- LH-RH derivatives include nafarelin, busecilin, zilidexin, etc.
- composition for the nasal transmucosal delivery including the peptide-polymer conjugate of the present invention can be formulated into the suitable form, and mainly administered by spray as a medicine for external use.
- the peptide-polymer conjugate is dissolved in a solvent, or a suspended, medicinal solution is filled in a container having a specific spraying device (valve) with a low viscous spraying agent.
- a specific spraying device valve
- the medicinal solution is sprayed in the type of smog using pressure.
- the material quality of container uses a metal such as a tinned iron and aluminum.
- the inside of container is coated with moth-proof painting.
- the container made of glass or synthetic resin is possible.
- the spraying agent uses generally a compressed air and an incombustible liquefied gas, freon(freon 11, CC 13 F; freon 12, CC 1£ F; freon 114, C 2 C 12 F 4 ).
- a dose of the pharmaceutical compositions containing the peptide-polymer conjugate of the present invention is 0.1 ug - 10 mg/kg/day, and can be widly altered according to the kind of peptide and patient's condition.
- sCT calcitonin-phosphate buffered saline
- PBS pH 7.4
- PEG (MW 12000) was activated with succinimidyl succinate, and PEG12000-sCT was prepared by using 9.2 mg of the activated SS-PEG. All procedures were performed as indicated in the Example ⁇ 1-1>.
- PEG (MW 2000) was activated with succinimidyl succinate, and PEG2000-sCT was prepared by using 2 mg of the activated SS-PEG. All procedures were performed as indicated in the Example ⁇ 1-1>.
- Example 2 Isolation of PEG-sCT PEG-sCT conjugates prepared in the Examples ⁇ 1-1> to ⁇ l-3> were isolated with the aid of size exclusion column (Super HR 12/30, PharmaciaLKB, Sweden) using PBS (pH 7.0) as eluent at 0.4 ml/min of flow rate (FIG. 1).
- FIG. 1 represented a fluorescence intensity of each peak measured by fluorescence spectrometer wherein each peak was eluted from the size-exclusion column.
- tri-PEG-sCT which was conjugated 3 molecules of PEG with 1 molecule of calcitonin and had a biggest molecular size, was firstly eluted from the column and collected within 30 minutes after sample injection into the column. After the tri-PEG-sCT, di-PEG-sCT and mono-PEG-sCT were isolated in succession. In addition, since calsitonin molecule conjugated with PEG had the smallest molecular size, it was eluted last from the column and time for elution took more 40 minutes. That time, the fluorescence intensity of each peak eluted from the column had measured by the fluorescence spectrometer directly connected to the column, and each peak was collected.
- Example 3 Preparation of PEG-sCT According to Various pHs , Molar Ratios and Reaction Times
- PEG-sCT conjugates prepared in Examples ⁇ 3-l> to ⁇ 3-3> were separated into tri-PEG-sCT, di-PEG-sCT and mono-PEG- sCT . This separation was conducted in a similar manner to that of Example 2.
- the mono-PEG-sCT obtained was divided into three isomers by reverse phase high performance liquid chromatography (HPLC) .
- HPLC high performance liquid chromatography
- the gradient condition was changed with 36-42 % solvent B (0.1 % PFPA added acetonitrile) and 64-58 % solvent A (0.1% PFPA added distilled water).
- Quantitative measurements were made using a UV absorption meter (215 mm) or a fluorescent absorption meter (excitation 280 nm, emissm 315 nm) .
- 0.1 M PBS, pH 7.0 was added with 50 ⁇ l of a PTH solution (2.4 mg/0.15 ml, 0.1 M PBS, pH 7.0) to give a mixture containing a molar ratio of 5:1 of SS- PEG5000:PTH.
- the mixture was allowed to react for 30 mm at ambient temperature with shaking. After 30 mm of the reaction, an excess amount of a 0.1 M glycme solution was added to stop the reaction. Unreacted parathyroid gland hormone and PEG were removed by dialysis using PBS to obtain PEG5000-PTH (1-34 ) .
- the PEG 5000-PTH (1-34) conjugate thus prepared was purified by size-exclusion chromatography using an HPLC system and superdex.
- PBS pH 7.0
- Eluted fractions were stored at 4C° until they were measured for UV absorbance. UV absorbance was measured at 215 nm while the excitation and emission waves of fluorescence were fixed in the range of 280 to 315 nm, as shown in Fig. 5.
- PEG2000-PTH (1-3 ) conjugates were prepared and isolated in a similar manner to that of Example ⁇ 5-l> except that SS-PEG2000 was used at an amount of 2 mg .
- GHRP-6 prepared PEG-GHRP-6, and isolated and purified as indicated in the Example ⁇ 5-l>. Isolated mono-PEG- GHRP-6 was immediately frozen-dried by freeze dryer.
- PEG2000 GHRP-6 conjugate as indicated in the Example ⁇ 6-l>.
- SS-PEG5000 (23 mg/0.20 ml, MW 5,000, 0.1 M PBS, pH 7.0) was added with 50 ⁇ l of a LHRH solution (0.5 mg/0.1 ml, 0.1 M PBS, pH 7.0) to give a mixture containing a molar ratio of 1:5 of LHRH: SS-PEG, prepared PEG-LHRH, and isolated and purified as indicated in the Example ⁇ 5-l>.
- PEG2000-LHRH conjugate was prepared, isolated and purified as indicated in the Example ⁇ 7-l>.
- Example 8 Preparation and Isolation of PEG5000- triptorelin Except for use of triptorelm, LHRH derivative, instead of LHRH, PEG5000-tr ⁇ ptorelm conjugate was prepared, isolated and purified as indicated m the Example ⁇ 7-l>.
- LHRH agonist instead of LHRH, PEG5000-ornt ⁇ de conjugate was prepared, isolated and purified as indicated in the Example ⁇ 7-l>,
- SD (Spraque Dawley) male rat (220 - 300 g, Charles River Japan, Atsugi, Japan) was put under anesthesia by administrating 45 mg/kg of peptobarbital into terperitoneal .
- Bronchus and esophagus were cannulated with PE-250 tube and thigh arteria with SP- 45 tube.
- 20 ul of a placebo and experimental drugs were administered into the nasal cavity of rats with Hamilton syringe.
- the placebo used physiological saline and the experimental drug used PEG5000-SCT, PEG12000-sCT, PEG2000-sCT and sCT prepared from the Example 2.
- Salmon calcitonm was administered at dose of 0.05 to 4.5 IU per rat, and rats were grouped into 4.
- AUC area-under the curve
- ⁇ D ( % ) ( AUCca-plac-AUC C a-sC ⁇ ) / AUC C a-plac X 100
- AUC Ca -piac was AUC from placebo administration to 960 minutes
- AUC Ca -sc ⁇ was AUC from calcitonm and experimental drugs administration to 960 minutes .
- the calcium concentration of calcitonm conjugated without any PEG was decreased for 1 hour after the nasal transmucasal administration, but restored at the original concentration after 2 hours.
- the calcitonm reduction effect represented for 4 hours to 8 hours after the nasal transmucasal administration.
- the calcium reduction effect was significantly altered according to the molecular size of PEG.
- the nasal transmocosal delivery using the PEG conjugates of the present invention could reduce a used amount of calcitonm and side effects of drugs .
- Example 7 The calcium reduction effect of the mono-PEG-sCT isomers prepared from the Example 4 was measured as indicated in the Example 1 (FIG. 7) .
- isomers conjugated w th PEG at N-termmus and Lys 18 represented a better sustaining and effective calcium reduction effect than isomers conjugated with PEG at Lys 11 .
- Lys 18 isomers having a lower calcium reduction effect than N-termmus isomers represented a considerable reduction effect to sCT or Lys 11 isomers.
- PEG (MW 2000) was activated with succinimidyl succinate, and PEG2000-GLP-1 was prepared by using 2 mg of the activated SS-PEG. All procedures were performed as indicated m the Example ⁇ 1-1>. In addition, PEG2000-GLP-1 was isolated and purified as indicated in the Example ⁇ 5-l>.
- a pharmaceutical composition comprising a peptide-polymer conjugate for a nasal transmucosal delivery of the present invention increases the water solubility of peptide, which is sparingly soluble m water, improves a stability by protecting from being degraded by protease, and, consequently, reduces an administration number of drug to decrease side-effects induced by drug abuse.
- the pharmaceutical composition comprising a peptide-polymer conjugate for the nasal transmucosal delivery of the present invention is delivered through the nasal cavity, it allows drug activity to be expressed in a short period of time and improves a bioavailability .
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU64784/00A AU6478400A (en) | 1999-08-17 | 2000-08-07 | The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
EP00952020A EP1204427A4 (en) | 1999-08-17 | 2000-08-07 | The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
JP2001516573A JP2003507344A (en) | 1999-08-17 | 2000-08-07 | Nasal mucosal delivery of peptides conjugated with biocompatible polymers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1999/33984 | 1999-08-17 | ||
KR1019990033984A KR100345214B1 (en) | 1999-08-17 | 1999-08-17 | The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001012230A1 true WO2001012230A1 (en) | 2001-02-22 |
Family
ID=19607583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2000/000868 WO2001012230A1 (en) | 1999-08-17 | 2000-08-07 | The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
Country Status (6)
Country | Link |
---|---|
US (1) | US6506730B1 (en) |
EP (1) | EP1204427A4 (en) |
JP (1) | JP2003507344A (en) |
KR (1) | KR100345214B1 (en) |
AU (1) | AU6478400A (en) |
WO (1) | WO2001012230A1 (en) |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001024831A2 (en) * | 1999-10-04 | 2001-04-12 | Shearwater Corporation | Polymer stabilized neuropeptides |
US6815530B2 (en) | 2001-06-04 | 2004-11-09 | Nobex Corporation | Substantiallymonodispersed mixtures of polymers having polyethylene glycol moieties |
EP1477496A1 (en) * | 2002-02-01 | 2004-11-17 | Chugai Seiyaku Kabushiki Kaisha | Peg-conjugated pth or peg-conjugated pth derivate |
WO2005007714A1 (en) * | 2003-07-18 | 2005-01-27 | Japan Exlan Company Limited | Polymer sustainedly releasing amino acid derivative, cosmetic and fiber construct containing the polymer, method of producing the same and method of regenerating the same |
EP1569676A2 (en) * | 2002-11-08 | 2005-09-07 | Nobex Corporation | Calcitonin drug-oligomer conjugates, and uses thereof |
WO2006135930A2 (en) * | 2005-06-13 | 2006-12-21 | Nastech Pharmaceutical Company Inc. | Transmucosal delivery of peptide derivatives |
EP1779864A1 (en) * | 2004-07-14 | 2007-05-02 | Chugai Seiyaku Kabushiki Kaisha | Pth-containing preparation for transmucosal administration |
WO2008089426A2 (en) * | 2007-01-19 | 2008-07-24 | Hananja Ehf | Methods and compositions for the delivery of a therapeutic agent |
EP1973952A1 (en) * | 2006-01-23 | 2008-10-01 | Gwangju Institute of Science and Technology | Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same |
US7786133B2 (en) | 2003-12-16 | 2010-08-31 | Nektar Therapeutics | Chemically modified small molecules |
US7872095B2 (en) | 2004-07-19 | 2011-01-18 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
CN101531756B (en) * | 2009-04-16 | 2011-06-15 | 山东大学 | Method for preparing water soluble polyethylene glycol/polylactic segmented polycarbonate resin |
US8034618B2 (en) | 2001-12-18 | 2011-10-11 | Eldgenossische Technische Hochschule Zurich | PTH containing cell growth matrix |
US8067431B2 (en) | 2003-12-16 | 2011-11-29 | Nektar Therapeutics | Chemically modified small molecules |
US8114383B2 (en) | 2003-08-06 | 2012-02-14 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US8226942B2 (en) | 2007-12-28 | 2012-07-24 | Kuros Biosurgery Ag | PDGF fusion proteins incorporated into fibrin foams |
US8293869B2 (en) | 2005-12-16 | 2012-10-23 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
US8309122B2 (en) | 2001-07-06 | 2012-11-13 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US8323889B2 (en) | 2004-07-01 | 2012-12-04 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US8633153B2 (en) | 2002-04-04 | 2014-01-21 | Amgen Inc. | Transthyretin variants |
US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
US9241908B2 (en) | 2007-10-16 | 2016-01-26 | Biocon Limited | Orally administrable solid pharmaceutical composition and a process thereof |
US9289432B2 (en) | 2007-01-19 | 2016-03-22 | HANANJA EHF and UNIVERSITY OF ICELAND | Methods and compositions for the delivery of a therapeutic agent |
US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
KR19980018262A (en) * | 1996-08-01 | 1998-06-05 | 윌리엄 비.켐플러 | I / O port and RAM memory addressing technology |
US6638906B1 (en) * | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
US20040096437A1 (en) * | 2000-07-27 | 2004-05-20 | Bon-Hong Min | Pharmaceutical composition comprising arginine deiminasa for inhibiting angio-genesis |
WO2002009741A1 (en) * | 2000-07-27 | 2002-02-07 | Angiolab, Inc. | The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US20090281023A9 (en) * | 2001-06-04 | 2009-11-12 | Nobex Corporation | Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment |
WO2005004792A2 (en) * | 2003-06-24 | 2005-01-20 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment |
US6713452B2 (en) * | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
BR0210855A (en) * | 2001-07-06 | 2006-10-24 | Penwest Pharmaceuticals Compan | Method of Manufacturing Extended Release Formulations |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
AU2002337686B2 (en) * | 2001-09-26 | 2008-05-15 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
BR0314619A (en) * | 2002-09-18 | 2005-08-02 | Univ Montreal Ct Hospitalier Chum | Ghrh's analogs |
WO2004043396A2 (en) * | 2002-11-09 | 2004-05-27 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
EP1569683B1 (en) * | 2002-11-26 | 2010-03-03 | Biocon Limited | Modified natriuretic compounds, conjugates, and uses thereof |
US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
KR20060135661A (en) * | 2003-12-18 | 2006-12-29 | 노보 노르디스크 에이/에스 | Novel glp-1 compounds |
US7115561B2 (en) * | 2004-09-22 | 2006-10-03 | Patterson James A | Medicament composition and method of administration |
US20060147443A1 (en) * | 2004-12-22 | 2006-07-06 | Kuros Biosurgery Ag | Synthetic biomaterials having incorporated therein bioactive factors through enzymatically degradable linkages |
US20080207505A1 (en) * | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
PL2136850T3 (en) * | 2007-04-13 | 2012-07-31 | Kuros Biosurgery Ag | Polymeric tissue sealant |
WO2008151512A1 (en) | 2007-06-12 | 2008-12-18 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. | Site-specific pegylated linear salmon calcitonin derivatives |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
JP5657011B2 (en) * | 2009-10-29 | 2015-01-21 | コリア アドバンスド インスティチュート オブ サイエンス アンド テクノロジィ | Conjugate of catechol polyethylene glycol derivative and protein or peptide, and production method thereof |
WO2015005459A1 (en) * | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | Pharmaceutical composition for respiratory administration |
KR101964376B1 (en) | 2017-09-29 | 2019-04-01 | 주식회사 나이벡 | Pharmaceutical composition and Biomaterial Containing Fusion Peptide Comprising Parathyroid hormone(PTH) bonded Bone-selective Peptide |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
WO1998052614A2 (en) * | 1997-05-21 | 1998-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61267528A (en) * | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | Transnasal calcitonin agent containing absorbefacient |
US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
FR2675807B1 (en) * | 1991-04-23 | 1994-07-01 | Medgenix Group Sa | CONJUGATE OF CALCITONIN AND POLYETHYLENE GLYCOL. |
EP0588255A1 (en) * | 1992-09-12 | 1994-03-23 | Dott Limited Company | Physiologically active peptide compositions |
US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
IL118003A0 (en) * | 1996-04-23 | 1996-08-04 | Yeda Res & Dev | Novel vip fragments and pharmaceutical compositions comprising them |
US6165509A (en) * | 1998-09-01 | 2000-12-26 | University Of Washington | Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto |
-
1999
- 1999-08-17 KR KR1019990033984A patent/KR100345214B1/en not_active IP Right Cessation
-
2000
- 2000-08-07 WO PCT/KR2000/000868 patent/WO2001012230A1/en active Application Filing
- 2000-08-07 JP JP2001516573A patent/JP2003507344A/en active Pending
- 2000-08-07 EP EP00952020A patent/EP1204427A4/en not_active Withdrawn
- 2000-08-07 AU AU64784/00A patent/AU6478400A/en not_active Abandoned
- 2000-08-15 US US09/639,483 patent/US6506730B1/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
WO1998052614A2 (en) * | 1997-05-21 | 1998-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
Non-Patent Citations (1)
Title |
---|
See also references of EP1204427A4 * |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001024831A3 (en) * | 1999-10-04 | 2002-03-07 | Shearwater Corp | Polymer stabilized neuropeptides |
WO2001024831A2 (en) * | 1999-10-04 | 2001-04-12 | Shearwater Corporation | Polymer stabilized neuropeptides |
US8440623B2 (en) | 1999-10-04 | 2013-05-14 | Nektar Therapeutics | Polymer stabilized neuropeptides |
US8008435B2 (en) | 1999-10-04 | 2011-08-30 | Nektar Therapeutics | Polymer stabilized neuropeptides |
US6815530B2 (en) | 2001-06-04 | 2004-11-09 | Nobex Corporation | Substantiallymonodispersed mixtures of polymers having polyethylene glycol moieties |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US8309122B2 (en) | 2001-07-06 | 2012-11-13 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US8034618B2 (en) | 2001-12-18 | 2011-10-11 | Eldgenossische Technische Hochschule Zurich | PTH containing cell growth matrix |
EP1477496A1 (en) * | 2002-02-01 | 2004-11-17 | Chugai Seiyaku Kabushiki Kaisha | Peg-conjugated pth or peg-conjugated pth derivate |
EP1477496A4 (en) * | 2002-02-01 | 2006-08-02 | Chugai Pharmaceutical Co Ltd | Peg-conjugated pth or peg-conjugated pth derivate |
US8633153B2 (en) | 2002-04-04 | 2014-01-21 | Amgen Inc. | Transthyretin variants |
US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
EP1569676A4 (en) * | 2002-11-08 | 2008-10-08 | Biocon Ltd | Calcitonin drug-oligomer conjugates, and uses thereof |
EP1569676A2 (en) * | 2002-11-08 | 2005-09-07 | Nobex Corporation | Calcitonin drug-oligomer conjugates, and uses thereof |
WO2005007714A1 (en) * | 2003-07-18 | 2005-01-27 | Japan Exlan Company Limited | Polymer sustainedly releasing amino acid derivative, cosmetic and fiber construct containing the polymer, method of producing the same and method of regenerating the same |
US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
US8114383B2 (en) | 2003-08-06 | 2012-02-14 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
US7786133B2 (en) | 2003-12-16 | 2010-08-31 | Nektar Therapeutics | Chemically modified small molecules |
US9388104B2 (en) | 2003-12-16 | 2016-07-12 | Nektar Therapeutics | Chemically modified small molecules |
US8034825B2 (en) | 2003-12-16 | 2011-10-11 | Nektar Therapeutics | Chemically modified small molecules |
US8067431B2 (en) | 2003-12-16 | 2011-11-29 | Nektar Therapeutics | Chemically modified small molecules |
US11129794B2 (en) | 2003-12-16 | 2021-09-28 | Nektar Therapeutics | Chemically modified small molecules |
US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
US8323889B2 (en) | 2004-07-01 | 2012-12-04 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
EP1779864A4 (en) * | 2004-07-14 | 2010-10-20 | Chugai Pharmaceutical Co Ltd | Pth-containing preparation for transmucosal administration |
EP1779864A1 (en) * | 2004-07-14 | 2007-05-02 | Chugai Seiyaku Kabushiki Kaisha | Pth-containing preparation for transmucosal administration |
US9101596B2 (en) | 2004-07-19 | 2015-08-11 | Biocon Limited | Cation complexes of insulin compound conjugates, formulations and uses thereof |
US7872095B2 (en) | 2004-07-19 | 2011-01-18 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
US9102758B2 (en) | 2004-07-19 | 2015-08-11 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
US7875700B2 (en) | 2004-07-19 | 2011-01-25 | Biocon Limited | Cation complexes of insulin compound conjugates, formulation and uses thereof |
US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
WO2006135930A3 (en) * | 2005-06-13 | 2007-05-31 | Nastech Pharm Co | Transmucosal delivery of peptide derivatives |
WO2006135930A2 (en) * | 2005-06-13 | 2006-12-21 | Nastech Pharmaceutical Company Inc. | Transmucosal delivery of peptide derivatives |
US8580919B2 (en) | 2005-12-16 | 2013-11-12 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
US8293869B2 (en) | 2005-12-16 | 2012-10-23 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
EP1973952A4 (en) * | 2006-01-23 | 2010-09-01 | Kwangju Inst Sci & Tech | Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same |
EP1973952A1 (en) * | 2006-01-23 | 2008-10-01 | Gwangju Institute of Science and Technology | Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same |
US9289432B2 (en) | 2007-01-19 | 2016-03-22 | HANANJA EHF and UNIVERSITY OF ICELAND | Methods and compositions for the delivery of a therapeutic agent |
US10052333B2 (en) | 2007-01-19 | 2018-08-21 | University Of Iceland | Methods and systems for the delivery of a therapeutic agent |
US9687495B2 (en) | 2007-01-19 | 2017-06-27 | Hananja Ehf | Methods and systems for the delivery of a therapeutic agent |
WO2008089426A3 (en) * | 2007-01-19 | 2009-02-12 | Hananja Ehf | Methods and compositions for the delivery of a therapeutic agent |
WO2008089426A2 (en) * | 2007-01-19 | 2008-07-24 | Hananja Ehf | Methods and compositions for the delivery of a therapeutic agent |
US9241908B2 (en) | 2007-10-16 | 2016-01-26 | Biocon Limited | Orally administrable solid pharmaceutical composition and a process thereof |
US8226942B2 (en) | 2007-12-28 | 2012-07-24 | Kuros Biosurgery Ag | PDGF fusion proteins incorporated into fibrin foams |
US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
CN101531756B (en) * | 2009-04-16 | 2011-06-15 | 山东大学 | Method for preparing water soluble polyethylene glycol/polylactic segmented polycarbonate resin |
US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
Also Published As
Publication number | Publication date |
---|---|
EP1204427A1 (en) | 2002-05-15 |
KR20010018158A (en) | 2001-03-05 |
JP2003507344A (en) | 2003-02-25 |
KR100345214B1 (en) | 2002-07-25 |
AU6478400A (en) | 2001-03-13 |
US6506730B1 (en) | 2003-01-14 |
EP1204427A4 (en) | 2007-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6506730B1 (en) | Nasal transmucosal delivery of peptide conjugated with biocompatible polymers | |
US9682153B2 (en) | Polymer conjugates of therapeutic peptides | |
US10420844B2 (en) | Peptide pharmaceuticals | |
JP2851627B2 (en) | Nasal administration of powdered polypeptides | |
US6703381B1 (en) | Methods for delivery therapeutic compounds across the blood-brain barrier | |
US5482706A (en) | Transmucosal therapeutic composition | |
US20110171312A1 (en) | Modified therapeutic peptides, methods of their preparation and use | |
EP2710031B9 (en) | Improved peptide pharmaceuticals for insulin resistance | |
Youn et al. | Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection | |
LT5153B (en) | Pulmonary adminstration of chemically modified insulin | |
WO1990009167A1 (en) | Composition and method for administration of pharmaceutically active substances | |
Na et al. | Stability of PEGylated salmon calcitonin in nasal mucosa | |
Mezo et al. | New derivatives of GnRH as potential anticancer therapeutic agents | |
JPH06228199A (en) | Peptide binding body capable of passing through blood brain barrier | |
Youn et al. | Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation | |
Balasubramaniam et al. | Structure− activity studies including a ψ (CH2-NH) scan of peptide YY (PYY) active site, PYY (22− 36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine | |
JP2009536670A (en) | Compositions and methods for increasing cell permeability of compounds | |
AU2021399904A1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
JP3263598B2 (en) | Bioactive peptide composition for nasal absorption | |
JP2004002331A (en) | Treatment of liver cancer | |
Shin et al. | Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol | |
Mező | New Derivatives of GnRH as Potential Anticancer Therapeutic Agents Gábor Mező", Marilena Manea “, Ildikó Szabó", Borbála Vincze" and Magdolna Kovács | |
NZ617824B2 (en) | Improved peptide pharmaceuticals for insulin resistance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000952020 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000952020 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |